rs1060502104

Positions:

• chr19-11003381-C-T

Variant summary

Our verdict is Uncertain significance. Variant got 2 ACMG points: 3P and 1B. PM2 PP2 BP4

The NM_003072.5(SMARCA4):​c.1985C>T​(p.Ser662Leu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).

• Frequency: Genomes: not found (cov: 32)
• Consequence: SMARCA4 NM_003072.5 missense
• Clinical Significance: Uncertain significance criteria provided, multiple submitters, no conflicts U:4
• Conservation: PhyloP100: 4.63

Genes affected

SMARCA4 (HGNC:11100): (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) The protein encoded by this gene is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. Mutations in this gene cause rhabdoid tumor predisposition syndrome type 2. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]

SMARCA4 (HGNC:):

ACMG classification

Verdict is Uncertain_significance. Variant got 2 ACMG points.

• PM2: Very rare variant in population databases, with high coverage
• PP2: Missense variant in gene, where missense usually causes diseases (based on misZ statistic), SMARCA4. . Gene score misZ 6.8459 (greater than the threshold 3.09). Trascript score misZ 8.7957 (greater than threshold 3.09). GenCC has associacion of gene with uterine corpus sarcoma, Coffin-Siris syndrome 1, intellectual disability, autosomal dominant 16, rhabdoid tumor predisposition syndrome 2, familial rhabdoid tumor, hereditary nonpolyposis colon cancer, Coffin-Siris syndrome.
• BP4: Computational evidence support a benign effect (MetaRNN=0.30130905).

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
SMARCA4	NM_001387283.1	c.1985C>T	p.Ser662Leu	missense_variant	13/36	ENST00000646693.2	NP_001374212.1
SMARCA4	NM_003072.5	c.1985C>T	p.Ser662Leu	missense_variant	13/35	ENST00000344626.10	NP_003063.2

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
SMARCA4	ENST00000646693.2	c.1985C>T	p.Ser662Leu	missense_variant	13/36		NM_001387283.1	ENSP00000495368.1
SMARCA4	ENST00000344626.10	c.1985C>T	p.Ser662Leu	missense_variant	13/35	1	NM_003072.5	ENSP00000343896.4
SMARCA4	ENST00000643549.1	c.1985C>T	p.Ser662Leu	missense_variant	13/35			ENSP00000493975.1
SMARCA4	ENST00000541122.6	c.1985C>T	p.Ser662Leu	missense_variant	14/35	5		ENSP00000445036.2
SMARCA4	ENST00000643296.1	c.1985C>T	p.Ser662Leu	missense_variant	13/34			ENSP00000496635.1
SMARCA4	ENST00000644737.1	c.1985C>T	p.Ser662Leu	missense_variant	13/34			ENSP00000495548.1
SMARCA4	ENST00000589677.5	c.1985C>T	p.Ser662Leu	missense_variant	14/35	5		ENSP00000464778.1
SMARCA4	ENST00000643995.1	c.1397C>T	p.Ser466Leu	missense_variant	10/32			ENSP00000496004.1
SMARCA4	ENST00000644963.1	c.629C>T	p.Ser210Leu	missense_variant	6/28			ENSP00000495599.1
SMARCA4	ENST00000644065.1	c.710C>T	p.Ser237Leu	missense_variant	6/27			ENSP00000493615.1
SMARCA4	ENST00000642350.1	c.470C>T	p.Ser157Leu	missense_variant	5/27			ENSP00000495355.1
SMARCA4	ENST00000643857.1	c.338C>T	p.Ser113Leu	missense_variant	4/25			ENSP00000494159.1

Frequencies

GnomAD3 genomes Cov.: 32

GnomAD4 exome Cov.: 31

GnomAD4 genome Cov.: 32

ClinVar

Significance: Uncertain significance

Submissions summary: Uncertain:4

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Intellectual disability, autosomal dominant 16 Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Genome-Nilou Lab

Jul 15, 2021

- -

Rhabdoid tumor predisposition syndrome 2 Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Labcorp Genetics (formerly Invitae), Labcorp

Oct 03, 2023

This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 662 of the SMARCA4 protein (p.Ser662Leu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 408711). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SMARCA4 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

not provided Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

GeneDx

Jul 14, 2023

Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -

Hereditary cancer-predisposing syndrome Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Ambry Genetics

Jul 12, 2024

The p.S662L variant (also known as c.1985C>T), located in coding exon 12 of the SMARCA4 gene, results from a C to T substitution at nucleotide position 1985. The serine at codon 662 is replaced by leucine, an amino acid with dissimilar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Missense and in-frame variants in SMARCA4 are known to cause neurodevelopmental disorders; however, such associations with rhabdoid tumor predisposition syndrome including small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) are exceedingly rare (Kosho T et al. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):262-75; Jelinic P et al. Nat Genet. 2014 May;46(5):424-6). Based on the supporting evidence, the association of this alteration with Coffin-Siris syndrome is unknown; however, the association of this alteration with rhabdoid tumor predisposition syndrome is unlikely. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Uncertain	0.36
BayesDel_addAF	Benign	-0.0037	T
BayesDel_noAF	Benign	-0.24
CADD	Pathogenic	26
DANN	Uncertain	1.0
DEOGEN2	Uncertain	0.66	D;.;T;.;.;.;.;.;.;.;D;.;.;.;.;.;T;T;.;.;.;.
Eigen	Uncertain	0.19
Eigen_PC	Benign	0.16
FATHMM_MKL	Pathogenic	0.99	D
LIST_S2	Pathogenic	0.99	.;D;.;.;.;.;D;.;.;.;D;.;D;D;D;D;D;D;D;D;D;T
M_CAP	Benign	0.082	D
MetaRNN	Benign	0.30	T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM	Benign	-0.86	T
MutationAssessor	Benign	1.8	L;.;.;.;L;L;.;L;L;L;L;L;L;L;L;L;.;.;.;.;.;.
PrimateAI	Uncertain	0.64	T
PROVEAN	Uncertain	-3.1	D;.;.;.;.;.;.;.;.;.;D;.;D;.;D;.;.;D;.;.;.;.
REVEL	Benign	0.12
Sift	Benign	0.033	D;.;.;.;.;.;.;.;.;.;D;.;D;.;D;.;.;D;.;.;.;.
Sift4G	Benign	0.27	T;.;.;.;.;.;.;.;.;.;T;.;T;T;T;T;T;T;.;.;.;.
Polyphen		0.87	P;.;P;.;.;.;.;.;.;.;P;.;.;.;.;.;.;P;.;.;.;.
Vest4		0.51
MutPred		0.26		Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);Loss of phosphorylation at S662 (P = 2e-04);.;Loss of phosphorylation at S662 (P = 2e-04);.;.;.;.;
MVP		0.55
MPC		2.0
ClinPred		0.95	D
GERP RS		3.2
RBP_binding_hub_radar		0.0
RBP_regulation_power_radar		1.2
Varity_R		0.20
gMVP		0.62

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs1060502104; hg19: chr19-11114057;